ATMI Finesses single-use bioreactors with process control tech deal
The deal, terms of which have not been disclosed, will see ATMI bundle the Finesse T700 control systems, which feature the latter’s range of TruFlour pH, dissolved oxygen and pressure, with its own Integrity PadReactor biomanufacturing technology.
ATMI CEO Doug Neugold told in-Pharmatechnologist.com about the new partnership at Interphex 2011, explaining that the bioprocess sector’s desire for precision control and quality were the key motivations.
“Finesse is a great company. They developed this technology and within five years they made it [meet with] GMP standards [good manufacturing practice]” explained Neugold, adding that the aim is to provide a complete solution.
He added that combining the two technologies will help customers get the best out of their biomanufacturing processes by providing improved mixing and, ultimately, increasing output.
